Role of interleukin-12 (IL 12) as an anti-tumour agent: experimental biology and clinical application

L. Zitvogel; M. T. Lotze

doi:10.1016/0923-2494(96)83041-0

Role of interleukin-12 (IL 12) as an anti-tumour agent: experimental biology and clinical application

L. Zitvogel, M. T. Lotze

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

17 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	628-638
Nombre de pages	11
journal	Research in Immunology
Volume	146
Numéro de publication	7-8
Les DOIs	https://doi.org/10.1016/0923-2494(96)83041-0
état	Publié - 1 janv. 1995
Modification externe	Oui

Accès au document

10.1016/0923-2494(96)83041-0

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{3ce2e844435440f6b15eaf9fbfac4614,

title = "Role of interleukin-12 (IL 12) as an anti-tumour agent: experimental biology and clinical application",

author = "L. Zitvogel and Lotze, {M. T.}",

note = "Funding Information: We proposed to the Recombinant DNA Advisory Commitee to the NIH in June 4, 1994 an IL12 gene therapy clinical protocol based on the utilization of TFG-hIL12-engineered autologous skin fibroblasts (Zitvogel et al., 1994a) from cancer patients, which will be directly injected into accessible tumour sites (head and neck tumours, breast carcinoma, melanoma) on a weekly basis (protocol schema, fig. 4). The first patient was treated on July 10, 1995, following approval by the Director of the National Institutes of Health and the US Food and Drug Administration.",

year = "1995",

month = jan,

day = "1",

doi = "10.1016/0923-2494(96)83041-0",

language = "English",

volume = "146",

pages = "628--638",

journal = "Research in Immunology",

issn = "0923-2494",

number = "7-8",

}

TY - JOUR

T1 - Role of interleukin-12 (IL 12) as an anti-tumour agent

T2 - experimental biology and clinical application

AU - Zitvogel, L.

AU - Lotze, M. T.

N1 - Funding Information: We proposed to the Recombinant DNA Advisory Commitee to the NIH in June 4, 1994 an IL12 gene therapy clinical protocol based on the utilization of TFG-hIL12-engineered autologous skin fibroblasts (Zitvogel et al., 1994a) from cancer patients, which will be directly injected into accessible tumour sites (head and neck tumours, breast carcinoma, melanoma) on a weekly basis (protocol schema, fig. 4). The first patient was treated on July 10, 1995, following approval by the Director of the National Institutes of Health and the US Food and Drug Administration.

PY - 1995/1/1

Y1 - 1995/1/1

UR - http://www.scopus.com/inward/record.url?scp=0029584391&partnerID=8YFLogxK

U2 - 10.1016/0923-2494(96)83041-0

DO - 10.1016/0923-2494(96)83041-0

M3 - Article

C2 - 8839171

AN - SCOPUS:0029584391

SN - 0923-2494

VL - 146

SP - 628

EP - 638

JO - Research in Immunology

JF - Research in Immunology

IS - 7-8

ER -